50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%.

[0028] In some aspects, prior to treatment with the pharmaceutical composition the subject is administered an immunosuppressant. In some aspects, the immunosuppressant is prednisone.

[0029] In some aspects, the prednisone is administered at a dosage of: 40 mg, once daily 1 week prior to AAV viral vector administration; 40 mg once daily for week 1 through week 2 post-AAV viral vector administration; 30 mg once daily for week 3 post-AAV viral vector administration; 20 mg once daily for week 4 post-AAV viral vector administration; 10 mg once daily for week 5 post-AAV viral vector administration; 5 mg once daily for week 6 post-AAV viral vector administration; 2.5 mg once daily for week 7 post-AAV viral vector administration; and 2.5 mg every other day for week 8 post-AAV viral vector administration.

[0029a] In one aspect, the present disclosure refers to use of a pharmaceutical composition as described herein in the manufacture of a medicament for treating Alzheimer's disease in a human subject, wherein the pharmaceutical composition is to be administered in a therapeutically effective amount.

[0029b] In one aspect, the present disclosure refers to the pharmaceutical composition as described herein for use in therapy.

[0030] Any of the above aspects, or any other aspect described herein, can be combined with any other aspect.

[0031] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. In the Specification, the singular forms also include the plural unless the context clearly dictates otherwise; as examples, the terms "a," "an," and "the" are understood to be singular or plural and the term "or" is understood to be inclusive. By way of example, "an element" means one or more element.

[0032] Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. The references cited herein are not admitted to be prior art to the claimed invention. In the case of conflict, the present Specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting. Other features and advantages of the disclosure will be apparent from the following detailed description and claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[0033] FIG. 1A is a table showing APOE variants. The APOE Alzheimer's disease risk region (amino acids 112-158) includes APOE3 (average risk), APOE4 (high risk) and APOE2 (low risk). Shown also is the sequence of the Columbian APOE3Ch variant and the